­
­
­
­

Inventi Impact: Cardiology & Haematology

Articles

  • Inventi:hch/25025/18
    Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse\nLarge B Cell Lymphoma Patients
    01-Jan-1970 Research 2018 : April - June
    Kamel Ait-Tahar, Amanda P Anderson, Martin Barnardo, Graham P Collins, Chris S R Hatton, Alison H Banham, Karen Pulford

    Improved therapies are urgently needed for patients with diffuse large B cell lymphoma(DLBCL). Success usingimmune checkpoint\ninhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer\ntestis antigens (CTAs), with their widespread expression inmany tumours but highly restricted normal tissue distribution, represent\nattractive immunotherapeutic targets that may improve treatment options for DLBCL and other malignancies. Sperm protein 17\n(Sp17), a CTA reported to be immunogenic in ovarian cancer andmyeloma patients, is expressed in DLBCL. The aimof the present\nstudy was to investigate Sp17 epitope presentation via the presence of a cytotoxic T cell (CTL) and a CD4 T-helper (Th) response\nin DLBCL patients. A significant

    How to Cite this Article
    CC Compliant Citation: Kamel Ait-Tahar, Amanda P. Anderson,\nMartin Barnardo et al., â??Sp17 Protein Expression and Major\nHistocompatibility Class I and II Epitope Presentation in Diffuse\nLarge B Cell Lymphoma Patients,â? Advances in Hematology, vol.\n2017, Article ID 6527306, 9 pages, 2017,\ndoi:10.1155/2017/6527306, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text